FDA Approves Lucentis Biosimilar Nufymco - Top-Institutions - MDSpire

FDA Approves Lucentis Biosimilar Nufymco

Ranibizumab-leyk (Nufymco) is approved for all Lucentis indications.

  • By

  • Conexiant News Staff

  • January 2, 2026

  • 1 min

Share

Top Institutions in Ophthalmology

Brief introduction explaining scope and methodology.

  • #1

    Bascom Palmer Eye Institute
    Bascom Palmer Eye Institute

    Miami, FL

    Key Differentiators

    • Ophthalmology
    • Retina
    • Clinical Trials

  • #2

    Massachusetts Eye and Ear Infirmary
    Massachusetts Eye and Ear Infirmary

    Boston, MA

    Key Differentiators

    • Ophthalmology
    • Retina
    • Translational Research

  • #3

    Wills Eye Hospital
    Wills Eye Hospital

    Philadelphia, PA

    Key Differentiators

    • Ophthalmology
    • Retina
    • Clinical Research

  • #4

    Johns Hopkins Wilmer Eye Institute
    Johns Hopkins Wilmer Eye Institute

    Baltimore, MD

    Key Differentiators

    • Ophthalmology
    • Retina
    • Biomedical Research

Original Source(s)

FDA Approves Lucentis Biosimilar Nufymco

  • by Conexiant News Staff

  • January 2, 2026

Related Content

Myopia Severity Tied to Pediatric Retinal Pathology

Routine dilated examinations identified peripheral retinal abnormalities across refractive groups, with higher pathology rates among patients with at least 3.00 D of myopia

Angular Threshold for Intraocular Pressure Elevation during Robot-Assisted Radical Prostatectomy in Trendelenburg Position

Artificial intelligence framework for multi-pathology risk assessment from retinal fundus images: deep learning approach to 15-disease screening